Alterity Therapeutics (ATHE) has released an update.
Alterity Therapeutics Limited has announced the cessation of 5 million options due to unmet conditions, effective May 7, 2024. This cessation follows the lapse of conditional rights to securities, specifically options expiring on November 29, 2026, with an exercise price of $0.0375. The company’s issued capital will now comprise different classes of quoted and unquoted equity securities, excluding the ceased options.
For further insights into ATHE stock, check out TipRanks’ Stock Analysis page.
